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ABSTRACT 
Background: PET/CT, positron emission tomography combined with computed tomography, 
with 
18
F-FDG (2-deoxy-2-[
18
F]fluoro-D-glucose) is well established in oncological imaging. 
Pulmonary carcinoid tumours may have metabolic activity, making them available for PET/CT 
imaging with 
18
F-FDG.  
Positron-emitting isotope-labelled somatostatin analogues, such as DOTATOC (DOTA = 
1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid, TOC = D-Phe
1
-Tyr
3
-Octreotide), 
have during the last years become more widely available for imaging of abdominal 
neuroendocrine neoplasms by PET.  
68
Ga -DOTATOC PET is recommended by the latest version of the National Care Program for 
neuroendocrine abdominal tumours (2018) in Sweden, for the imaging work-up of patients with 
suspected or verified abdominal neuroendocrine tumour, 
https://www.cancercentrum.se/samverkan/cancerdiagnoser/neuroendokrina-
buktumorer/vardprogram/gallande-vardprogram/, [cited 2019 aug 15].  
Pulmonary carcinoid tumours exhibit somatostatin receptors (SSTRs). PET/CT with 
68
Ga-
DOTATOC presents the possibility of a more accurate evaluation of respiratory tract neoplasms 
such as pulmonary carcinoids. 
Purpose: To differentiate pulmonary carcinoids from pulmonary hamartomas and typical from 
atypical pulmonary carcinoids by means of 
18
F-FDG PET and/or 
18
F-FDG PET and 
68
Ga -
DOTATOC PET.  
Study I showed that 
18
F-FDG PET/CT can distinguish pulmonary carcinoids from pulmonary 
hamartomas with a negative predictive value (NPV) of 92% by applying a partial volume effect 
corrected for the maximum standardised uptake value (SUVmax ) of 1.5 as a cutoff. However, 
these 
18
F-FDG PET measurements do not allow for the distinction between atypical and typical 
pulmonary carcinoids.  
 Study II evaluated 
18
F-FDG PET/CT and 
68
Ga-DOTATOC PET/CT scans in pulmonary 
carcinoids in correlation with SSTR expression profiles, tumour proliferation and pulmonary 
carcinoid subtype (typical / atypical).  No correlation was found between 
18
F-FDG or 
68
Ga-
DOTATOC tracer uptake in PET/CT and tumour subtype (typical pulmonary carcinoid / 
atypical pulmonary carcinoid). Correlation between 
68
Ga-DOTATOC and 
18
F-FDG uptake, 
using the tumour-to-normal-liver ratio, and immunohistochemistry in tumours, regarded as 
somatostatin receptor subtype 2 (or 2 and 5), was investigated. Between 
68
Ga-DOTATOC and 
18
F-FDG uptake, an inverse imaging phenotype was shown in relation to the SSTR expression 
profile with high 
68
Ga-DOTATOC accumulation and low 
18
F-FDG uptake in carcinoids positive 
for SSTR subtypes 2 (or 2 and 5) and conversely, low 
68
Ga-DOTATOC accumulation and high 
18
F-FDG uptake in carcinoids negative for SSTR subtypes 2 (or 2 and 5). 
68
Ga-DOTATOC 
uptake was significantly higher for tumours expressing SSTR subtypes 2 (or 2 and 5) as 
compared to the tumours not expressing SSTR subtypes 2 (or 2 and 5). 
18
F-FDG uptake and Ki-
67 (a marker for cell proliferation) labelling index were significantly higher for tumours not 
expressing SSTR subtypes 2 (or 2 and 5) as compared to the other subgroups. 
68
Ga-DOTATOC 
and 
18
F-FDG uptake were found to reflect tumour grading (as formulated in the study), based on 
Ki-67 labelling index. 
Conclusions: It was possible to differentiate pulmonary carcinoids from hamartomas using PET 
measurements of the 
18
F-FDG-uptake in the tumours, corrected for partial volume effect. 
Clinically more aggressive, atypical pulmonary carcinoids could not be differentiated from 
typical pulmonary carcinoids by neither 
18
F-FDG PET/CT nor by 
68
Ga-DOTATOC PET/CT. In 
pulmonary carcinoid tumours, an increased 
68
Ga-DOTATOC uptake reflected somatostatin 
receptor subtype 2 and 5 expression. The genotypes in pulmonary carcinoids were reflected in 
the imaging phenotypes with inverse 
68
Ga-DOTATOC and 
18
F-FDG accumulation patterns 
related to the tumour somatostatin receptor profile and proliferative activity. 
  
  
SAMMANFATTNING 
Bakgrund: PET/CT, positronemissionstomografi i kombination med datortomografi, med 
18
F-
FDG (2-deoxy-2- [
18
F] fluoro-D-glukos) är väl etablerat vid onkologisk avbildning. Pulmonella 
karcinoida tumörer kan uppvisa metabolisk aktivitet, vilket gör dem tillgängliga för PET/CT-
avbildning med 
18
F-FDG.  
Positronemitterande isotopmärkta somatostatinanaloger, såsom DOTATOC (DOTA = 1,4,7,10-
tetraazacyklo-dodekan-1,4,7,10-tetraättiksyra, TOC = D-Phe1-Tyr3-Octreotide), har under de 
senaste åren blivit mer allmänt tillgängliga för avbildning med PET av abdominella 
neuroendokrina neoplasmer. 
68
Ga-DOTATOC PET rekommenderas i den senaste versionen av Nationellt vårdprogram för 
neuroendokrina buktumörer (2018) i Sverige för utredningen av patienter med misstänkt eller 
verifierad neuroendokrin tumör i buken, 
https://www.cancercentrum.se/samverkan/cancerdiagnoser/neuroendokrina-
buktumorer/vardprogram/gallande-vardprogram/, [läst 2019-08-15].  
Pulmonella karcinoida tumörer (lungkarcinoider) uppvisar somatostatinreceptorer (SSTR). 
68
Ga-DOTATOC (somatostatinanalog)  PET/CT ger möjligheten till en mer exakt utvärdering 
av neoplasmer i luftvägarna, såsom lungkarcinoider.  
Syfte: Att differentiera lungkarcinoider från hamartomer och typiska från atypiska 
lungkarcinoider med hjälp av 18F-FDG PET och/eller 18F-FDG PET och 68Ga-DOTATOC PET.  
Studie I visade att 
18
F-FDG PET/CT kan skilja pulmonella karcinoider från lunghamartomer 
med ett negativt prediktivt värde (NPV) på 92% genom att tillämpa en partiell volymeffekt- 
korrigerad maximalt standardiserat värde (SUVmax) på 1,5 som ett gränsvärde. Dessa
 18
F-FDG 
PET-mätningar medger emellertid inte separering av atypiska från typiska lungkarcinoider.   
Studie II utvärderade 18F-FDG PET/CT och 68Ga-DOTATOC PET/CT i lungkarcinoider i 
korrelation med SSTR-uttrycksprofiler, tumörproliferation och lungkarcinoid-subtyp (typisk / 
atypisk). Ingen korrelation hittades mellan 
18
F-FDG- eller 
68
Ga-DOTATOC- upptag med 
PET/CT och tumörsubtyp (typisk lungkarcinoid / atypisk lungkarcinoid). Korrelation mellan 
68
Ga-DOTATOC- och 
18
F-FDG- upptag, med användning av tumör- till normalt-lever- ratio, 
och immunohistokemi i tumörer för somatostatinreceptorsubtyp 2 (eller 2 och 5) blev 
undersökt. 68Ga-DOTATOC- och 18F-FDG- upptag visade gentemot varandra en omvänd 
avbildningsfenotyp i förhållande till SSTR-uttrycksprofilen, med hög 68Ga-DOTATOC-
ackumulering och lågt 18F-FDG-upptag i karcinoider positiva för SSTR-subtyperna 2 (eller 2 
och 5) och omvänt lågt 68Ga-DOTATOC-ackumulering och högt 18F-FDG-upptag i karcinoider 
negativa för SSTR-subtyper 2 (eller 2 och 5). 68Ga-DOTATOC-upptaget var signifikant högre 
för tumörer som uttryckte SSTR-subtyp 2 (eller 2 och 5) jämfört med  tumörer som inte 
uttryckte SSTR-subtyp 2 (eller 2 och 5). 
18
F-FDG-upptaget och Ki-67 (en markör för 
cellproliferation) index var signifikant högre för tumörer som inte uttryckte SSTR-subtyp 2 
(eller 2 och 5) jämfört med de andra subgrupperna. 68Ga-DOTATOC- och 18F-FDG- upptag 
visade sig återspegla tumörgradering (såsom formulerats i studien), baserat på Ki-67 index. 
Slutsats: Det var möjligt att differentiera lungkarcinoiderna från hamartomer med användning 
av PET-mätningar av 18F-FDG-upptag i tumörerna, korrigerade för partiell volymeffekt. 
Kliniskt mer aggressiva atypiska lungkarcinoider kunde inte differentieras från typiska 
lungkarcinoider med 
18
F-FDG PET/CT eller med 
68
Ga-DOTATOC PET/CT. I 
lungkarcinoidtumörer reflekterade ett ökat 68Ga-DOTATOC-upptag uttrycket av 
somatostatinreceptorsubtyp 2 (eller 2 och 5). Genotyperna i lungkarcinoider återspeglades i 
avbildande fenotyper med invers 
68
Ga-DOTATOC- och 
18
F-FDG- ackumuleringsmönster 
relaterade till tumörsomatostatinreceptorprofil och proliferativ aktivitet. 
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LIST OF ABBREVIATIONS 
AC Atypical pulmonary carcinoid tumour 
CT Computed tomography 
DOTATOC DOTA = 1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-
tetraacetic acid, TOC = D-Phe
1
-Tyr
3
-Octreotide 
DOTATATE DOTA = 1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-
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1
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3
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18
F]fluoro-D-glucose 
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F-FDG 
combined with computed tomography 
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Ga Radioactive nuclide of Gallium 
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Ga-DOTATATE 
68
Ga-labelled DOTATATE 
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Ga -DOTATOC PET/CT Positron emission tomography with 
68
Ga -DOTATOC 
combined with computed tomography 
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Ga-DOTA-SSA          
68
Ga-labelled somatostatin analogue 
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IHC Immunohistochemistry 
IRS Immunoreactive score 
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PET Positron emission tomography 
PET/CT Positron emission tomography combined computed 
tomography 
PC Pulmonary carcinoid tumour 
PPV Positive predictive value 
  
PVE Partial volume effect 
SCLC Small cell lung carcinoma 
SSA Somatostanin analogue 
SSTR1, SSTR2, SSTR3, 
SSTR4, SSTR5 
Somatostatin receptor subtypes 
SUV Standardised uptake value 
SUVmax Maximum standardised uptake value 
SUR Standardised uptake value ratio, the ratio of activity 
concentration in tumour and normal tissue 
TC Typical pulmonary carcinoid tumour 
VOI Volume of interest 
WHO World Health Organisation 
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1 INTRODUCTION 
1.1 BACKGROUND 
18
F-FDG PET/CT, positron emission tomography (PET) with 2-deoxy-2-[
18
F]fluoro-D-
glucose (
18
F-FDG) combined with computed tomography (CT) is well established in 
oncological imaging and integrated into the imaging work-up of patients with suspected 
pulmonary carcinoid tumours (PCs). It is important to identify PCs preoperatively for 
treatment planning. The low incidence of PCs (they comprise 2-5% of all primary lung 
malignancies and 20-30% of all neuroendocrine neoplasms) makes it difficult to perform 
prospective studies on this type of tumour in a large patient group
1-6
. Neuroendocrine 
neoplasms exhibit somatostatin receptors (SSTRs) with heterogeneous SSTRs distribution in 
pulmonary neuroendocrine neoplasms
7
. Radiologic imaging, using radiopharmaceuticals for 
PET other than 
18
F-FDG, such as 
68
Ga-labelled somatostatin analogues (
68
Ga-DOTA-SSAs), 
reflecting the density of SSTRs in clinically suspected PC tumours, may be a helpful 
approach in an initial evaluation of the type of malignancy for effective clinical management 
of PC patient. 
1.2 PULMONARY CARCINOIDS AND HAMARTOMAS 
The current World Health Organisation (WHO) classification of tumours of the lung, pleura, 
thymus and heart requires grouping together PCs (typical carcinoid and atypical carcinoid 
tumours), the small cell lung carcinoma (SCLC) and the large cell neuroendocrine carcinoma 
(LCNEC) in one category of neuroendocrine tumours
8
. Clinically characterised by 
aggressiveness, typical carcinoids (TCs) are low-grade malignant, atypical carcinoids (ACs) - 
intermediate-grade malignant, LCNECs and SCLCs are high-grade malignant
9
. In separating 
TC from atypical AC, histopathological features, mitotic count and presence or absence of 
necrosis are recommended. PCs are defined as TC when the number of mitoses per 2 mm
2
 < 
2 with no sign of necrosis, and as AC when the mitotic rate is 2-10 mitoses per 2 mm
2
 and/or 
with evidence of necrosis
8
. TCs are much more common while ACs are clinically more 
aggressive with a higher rate of vascular invasion, metastases and recurrences. Because of 
their distinctly different clinical behavior, patient management varies accordingly. While CT 
allows for tumour localisation and morphological characterisation of the lesion with regard to 
edge definition, contrast enhancement and nodal involvement, none of these radiological 
features is pathognomonic for any PC subtype. PCs are sometimes misdiagnosed. The 
majority of these tumours are centrally located (i.e. in a main, lobar or segmental bronchus), 
and easy to diagnose by bronchoscopy. PCs arising in distal to segmental bronchi are 
radiologically considered as peripheral. Peripheral PCs provide a diagnostic challenge since 
they cannot be assessed by bronchoscopy. If a hamartoma (the most frequent benign lung 
tumour) or peripheral PC presents as a small lesion, both bronchoscopic biopsy and CT-
guided biopsy may be difficult. Needle biopsy may produce false negative results. It is not 
always easy to distinguish PCs from other tumour types by radiological imaging. 
Nevertheless, on a CT scan, high attenuation and high contrast-enhancement are indicative of 
a carcinoid tumour, whereas a hamartoma is characterised by smooth nodule edge, fat content 
 2 
and popcorn like calcifications
10
. On chest X-ray and CT, differentiation between a malignant 
tumour and a hamartoma can prove difficult when the latter lacks characteristic tissue 
components. Also, the presence of fat in a lung nodule does not always exclude malignancy. 
According to the data reported in literature and experience from our Institution, in a great part 
of the clinically assessed cases there is a lack of characteristic radiological criteria for a 
hamartoma. As a result of this - a need to employ additional diagnostic methods is required. 
For a differential diagnosis, a further diagnostic workup is therefore often needed, usually 
comprising 
18
F-FDG PET with CT (
18
F-FDG PET/CT)
10-12
. 
1.3 18F-FDG PET/CT 
PET/CT with 
18
F-FDG is well established in oncological imaging. Despite many publications 
about 
18
F-FDG PET/CT imaging of lung malignancies, the studies include a limited number 
of PC patients
3,13-19
. There are several reports demonstrating 
18
F-FDG avid TCs
3,17,19 
and 
ACs
13
. ACs have a tendency to show sufficiently high 
18
F-FDG uptake because of their 
higher mitotic count, while pulmonary hamartomas show no or low uptake. This can be 
helpful to differentiate PCs from hamartomas
12
. A TC with an extensive oncocytic 
component showing an intense 
18
F-FDG uptake was demonstrated in individual case reports 
by several investigators
17,19
. Suemitsu et al. reported a TC with distant metastasis showing 
high
 18
F-FDG uptake at the primary site and liver metastasis
3
. Erasmus et al. demonstrated 
TCs with low 
18
F-FDG uptake as did half of the patients with TCs in a study by Krüger et 
al.
13,15. However, the studies by Erasmus et al. and Krüger et al. were limited by their size (7 
and 13 patients, respectively)
13,15
. 
18
F-FDG PET/CT is considered less well suited for 
imaging of neuroendocrine tumours with low proliferation rate, such as PCs
13,20-22
. PCs are 
slow growing and their generally discrete 
18
F-FDG uptake may lead to false-negative results. 
Further, the recent study by Panagiotidis et al. demonstrated that 
18
F-FDG PET/CT has no 
clinical impact on well-differentiated neuroendocrine tumours and a moderate clinical impact 
on intermediate-differentiated neuroendocrine neoplasms
23
. 
1.4 SOMATOSTATIN RECEPTORS 
The human SSTR subtypes are SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5. For peptides 
like somatostatin, the binding to the receptors occurs at the extracellular loop segments and 
the superior parts of the transmembrane helices (Figure 1A, 1B, 1C). During evolution, 
receptor subtypes evolved from preceeding receptors after a gene duplication. Amino acids, 
important for the function of the original receptor, tend to stay conserved during the 
divergence. The seven transmembrane helices stay highly conserved between receptor 
subtypes (Fig. 1A). These helices are important for the localisation of the receptor in the 
plasma membrane and for the transduction of the activation signal from the extracellular 
ligand-binding site to the intracellular side of the cell. Functionally, the ligand-binding site 
should be fairly well conserved in order to retain the recognition of the ligand. The presence 
of 2-5 subtypes, within a receptor type, is not uncommon. The different subtypes may 
execute various physiological effects in the body, depending on their respective tissue 
localisation, expression level, binding affinity for hormones and drugs, intracellular 
 3 
signalling, etc. Lung neuroendocrine neoplasms have heterogeneous distribution of SSTR 
with decreased expression of SSTR2 and SSTR3 from low-grade/intermediate-grade (PCs) to 
high-grade (SCLC and LCNEC) tumours
7
. Among the SSTRs, SSTR subtype 2 (SSTR2) 
shows high expression in human neuroendocrine neoplasms
24,25
. The SSTR2 receptor has 
been proposed for evaluation with somatostatin analogues
7,26,27
. 
 
 
 
 
Figure 1A. Human somatostatin receptor subtype 2 (SSTR2). Each circle represents one 
amino acid. The horisontal lines define the inner and outer borders of the plasma membrane. 
There are seven transmembrane helices. The N-terminus, starting with a methionine (M), is 
situated extracellular, while C-terminal end is situated intracellular. 
The human somatostatin receptor sequences were retrieved from the UniProt database. 
[Retrieved 2018-07-27]. Available from: https://www.uniprot.org/uniprot/P30874 
The 2D snakeplot of SSTR2 was retreived from the database GPCR - SSFE 2.0   
(a homology modeling resource for G-protein coupled receptors). [Retrieved 2018-07-27]. 
Available from: http://www.ssfa-
7tmr.de/ssfe2/snakes/refine_designer_neu.php?jobid=1510586369&%20name=ssr2_human  
The final figure was constructed manually 
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Figure 1B. Human somatostatin receptor subtype 4 (SSTR4). Each circle represents one 
amino acid. 
The human somatostatin receptor sequences were retrieved from the UniProt database. 
[Retrieved 2018-07-27]. Available from: https://www.uniprot.org/uniprot/P31391 
The 2D snakeplot of SSTR4 was retreived from the database GPCR - SSFE 2.0   
(a homology modeling resource for G-protein coupled receptors). [Retrieved 2019-07-26]. 
Available from: http://www.ssfa-
7tmr.de/ssfe2/snakes/refine_designer_neu.php?jobid=1510586709&%20name=ssr4_human 
The final figure was constructed manually. 
  
 5 
 
Figure 1C. Human somatostatin receptor subtype 5 (SSTR5). Each circle represents one 
amino acid. 
The human somatostatin receptor sequences were retrieved from the UniProt database. 
[Retrieved 2018-07-27]. Available from: https://www.uniprot.org/uniprot/P35346 
The 2D snakeplot of SSTR5 was retreived from the database GPCR - SSFE 2.0   
(a homology modeling resource for G-protein coupled receptors). [Retrieved 2019-07-26]. 
Available from: http://www.ssfa-
7tmr.de/ssfe2/snakes/refine_designer_neu.php?jobid=1510586756&%20name=ssr5_human 
The final figure was constructed manually. 
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1.5 68GA-DOTATOC PET/CT 
The somatostatin analogue (SSA), DOTATOC (DOTA = 1,4,7,10-tetraazacyclo-dodecane-
1,4,7,10-tetraacetic acid, TOC = D-Phe
1
-Tyr
3
-Octreotide), shows a high affinity for SSTR2, 
SSTR5, and a moderate affinity for SSTR3
24,28,29
. Imaging with 
68
Ga-DOTA-SSAs, reflecting 
SSTR expression, is well established in oncological imaging and in many centers is 
integrated into the imaging workup of patients with suspected or verified abdominal 
neuroendocrine neoplasms. 
68
Ga-DOTA-SSAs are used extensively throughout the world in 
the last several years for guiding the management of many categories of neuroendocrine 
neoplasm patients
23,30-32
. Studies on PET using 
68
Ga-DOTA-SSAs, improved the accuracy of 
staging of patients with neuroendocrine neoplasm and showed PET with SSAs to be 
equivalent or superior to SSTR scintigraphy with 
111
In-labelled SSA in the detection of 
manifestations of neuroendocrine neoplasms
33-36
. General agreement nowadays is that 
PET/CT with SSAs should replace 
111
In-labelled SSA scintigraphy in all indications in which 
the latter is currently being used by medical practitioners
37,38
. Published reports on 
68
Ga-
DOTATOC PET/CT in patients with respiratory tract neoplasms merely include a limited 
number of patients with PCs
12,18,39,40
. Menda et al. demonstrated the value of 
68
Ga-
DOTATOC PET/CT in localisation of unknown primary tumour in patients with metastatic 
neuroendocrine neoplasm
41
. 
1.6 IMMUNOHISTOCHEMISTRY AND HISTOPATHOLOGY  
The standard method to measure SSTR in vitro is through immunohistochemistry (IHC) on 
formalin-fixed, paraffin-embedded tissue
25
. IHC requires tissue samples obtained through an 
invasive procedure. SSTR-immunohistochemistry correlates with 
68
Ga-DOTA-peptide PET 
results positively
26,27,42
. Similarly, it has been shown that SSTR2-immunohistochemistry also 
correlates well with 
68
Ga-DOTATOC PET
27
. 
Cancers could be characterised by their proliferative activity as measured by antibodies 
against the protein Ki-67, using IHC. The PCs grading based on Ki-67 labelling index is 
under debate. The Ki-67 index may be useful in estimating tumour progression in PCs
43,44
. 
However, even this evaluation requires tissue sampling involving biopsy or surgery. The 
assessment of tumour proliferation by a non-invasive PET method, by quantifying a degree of 
(hypothesised) correlation between the histologic grade of tumour, Ki-67 labelling index and 
PET/CT scan with 
68
Ga-DOTA-SSAs, is of interest to individualise the treatment and achieve 
prognostic information which may have consequences for the patient's treatment
23,27,45
. 
Panagiotidis et al. stated that in line with the fact that the maximum standardised uptake value 
(SUVmax) on 
68
Ga-DOTATATE (DOTA, TATE= D-Phe
1
-Tyr
3
-Octreotate) PET/CT 
correlates with Ki-67 index, 
68
Ga-DOTATATE can be used to assesss prognosis of patients 
with neoroendocrine neoplasm
23
. On the other hand, the study by Haug et al. states a lack of 
significant correlation between 
68
Ga-DOTATATE PET/CT and Ki-67 index in a 
neuroendocrine neoplasm patient population (only three of 27 were lung tumour patients)
42
. 
Similarly, no correlation was found between 
68
Ga-DOTATOC uptake in neuroendocrine 
neoplasms and Ki-67 index in a study by Miederer et al.
27
. The data related to the subject is 
discrepant in publications. 
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1.7 PARTIAL VOLUME EFFECT AND QUANTIFICATION OF TUMOUR 
UPTAKE 
In tumours and other tissues the standardised uptake value (SUV) is routinely used to 
quantify the PET tracer uptake. The SUV is achieved by dividing the radioactivity 
concentration (Bq/ml), for each pixel in the PET images, by the injected amount of 
radioactivity (Bq) per body-weight (g). As the SUV assumes a tissue density of 1g/ml, this 
approximation will be adequate for soft tissues but not for lung tissue.  
Factors influencing the SUV are both PET camera based and patient-related
46-49
. An 
important factor influencing the SUV, the partial volume effect (PVE), has a major impact on 
the quantification of tumour uptake. The PVE depends on the spatial resolution of the PET 
system (approximately 0.5 cm) and the distribution of the tracer uptake in the tumour and 
surrounding tissues
49
. The PVE correction introduces an object size dependent quantification. 
The standard way to determine the impact of the PVE on PET image quantification is to use 
the NEMA IEC Body Phantom Set, with the same homogeneous activity concentration in all 
spheres
50
. Respiratory movements during PET acquisition also contribute to image blur. The 
contribution to image blur in lung tissue is up to three times larger than in soft tissues and 
fat
47
. Approaches for correcting the blurring are still under evaluation
46,50
.   
The tracer uptake can be characterised, instead of SUV, by the standard uptake ratio (SUR), 
defined as the ratio of activity concentrations in tumour and, for example, aorta or normal 
liver.  Normal liver hepatocytes are negative for all five SSTR subtypes
51
.  
There are several problems regarding quantitative imaging using 
68
Ga-DOTA-SSAs. The 
methodology for accurate in vivo quantification of 
68
Ga-DOTA-peptide uptake is not 
established. It was found in a study on PET/CT with 
68
Ga-DOTATATE and 
68
Ga-
DOTATOC that the SUV does not reflect the SSTR expression for neuroendocrine 
neoplasms with high tracer accumulation
52,53
. Moreover, measurements in tracer 
accumulation can be affected by the amount of administered active substance in tumours and 
normal tissues
54
. Because of the longer mean range of the 
68
Ga positron, 
68
Ga PET imaging 
has lower sensitivity and worse spatial resolution relative to 
18
F PET imaging
50
. The PVE 
makes activity quantification more inaccurate with 
68
Ga than 
18
F. Unless proper corrections 
for the PVE are applied, quantification of 
68
Ga-based PET imaging with SUV should be 
performed with caution
46
. In PET literature, the results of tracer uptake measurements in 
tumors and normal tissues are widely reported, generally without taking the PVE into 
consideration. Even reference value, SUVmax, suggested as “cutoffs” to distinguish benign 
from malignant tumours, is usually presented without considering the lesion size. However, 
the scientifically correct way to perform a quantitative inter-patient comparative PET study, 
is with PVE corrected values
55,56
. Uncorrected SUV values merely represent the investigated 
cohort with the specific PET scanner and cannot be extrapolated to a general patient 
population. PVE corrected SUV values can be compared between patients and PET centres.  
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2 AIMS OF THIS THESIS 
 
It is important to identify PCs preoperatively for treatment planning. So far, there are a 
limited number of reports evaluating the use of 
18
F-FDG-PET/CT and 
68
Ga-DOTATOC-
PET/CT in patients with PCs, and within those reports the numbers of PC patients are few.  
 
Study I       To differentiate PCs from pulmonary hamartomas by means of 
18
F-FDG   
PET/CT.   
To analyse whether it is possible, using PET measurements of 
18
F-FDG in the 
tumours, corrected for PVE, to distinguish TCs from ACs.  
Study II  To obtain, in a prospective study, PVE corrected tumour uptake measurements on 
PET/CT with 
68
Ga-DOTATOC and 
18
F-FDG, using the tumour-to-normal-liver 
SUV ratio (SUR).  
To assess if 
18
F-FDG and 
68
Ga-DOTATOC accumulation in PCs correlates with 
tumour proliferation (Ki-67 labelling index). 
To analyse whether, using PET measurements of 
18
F-FDG and 
68
Ga-DOTATOC, 
it is possible to distinguish TCs from ACs. 
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3 MATERIALS AND METHODS 
The studies were approved by the Regional Ethical Board (2012/1921-31/1) and the 
Hospital’s Radiation Protection Committee (K2696-2012). 
3.1 PATIENTS 
Study I:  A retrospective analysis of 87 out of 118 patients with a histopathologically proven 
diagnosis of PC or pulmonary hamartoma, surgically resected at the Karolinska University 
Hospital, Stockholm, Sweden between Oktober 2005 and February 2012 and who had also 
undergone 
18
F-FDG PET/CT preoperatively. 31 patients were excluded as they had not 
undergone preoperative thoracic 
18
F-FDG PET/CT. All patients were referred to 
18
F-FDG 
PET/CT on the suspicion of lung cancer based on chest X-ray and in some cases equivocal 
findings on CT. Patients with PCs rarely express elevated biochemical tumour markers and 
this was also the case in the present group of PC patients in whom biochemistry in this regard 
was normal.  
The final diagnosis was based on the histopathological examination of surgical specimens. 
The PCs were further subclassified as TC or AC based on the World Health Organization’s 
criteria
57
.  
Study II:  All patients at the Karolinska University Hospital, Stockholm, Sweden between 
March 2013 and September 2015 with a strong suspicion or established diagnosis of PC 
tumour and planned for surgical resection were asked to participate in this study. The patients 
were initially referred to 
18
F-FDG PET/CT on the suspicion of lung cancer based on CT. 
Patients with suspected PC were asked for participation in this study and were consequently 
referred to 
68
Ga-DOTATOC PET/CT. The time interval between the two PET examinations 
was 28.5 days. The final diagnosis was based on histopathological examination of surgical 
specimens. The PCs were subclassified as TC or AC based on the WHO’s criteria8. Final 
patient inclusion criteria was a histopathological confirmed diagnosis of PCs from surgical 
specimens. 
3.2 PET IMAGING 
All patients in study I underwent preoperative PET/CT examination with 
18
F-FDG. All 
patients in study II underwent two preoperative PET/CT examinations, first with 
18
F-FDG 
and then, within approximately 1 month, with 
68
Ga-DOTATOC. All PET/CT examinations 
were performed on a Biograph 64 TruePointTrueV PET/CT scanner (Siemens Medical 
Solutions, Erlangen, Germany). 
18
F- PET/CT was performed 1 hour after intra-venous (i.v.) 
injection of 4 MBq/kg body-weight of 
18
F-FDG. 3 MBq/kg body-weight of 
68
Ga-DOTATOC 
was injected as an intravenous bolus, the mean time of examination registration after 
injection was 45 min. Patients were scanned from the base of skull to proximal thighs. A low-
dose CT for photon scatter correction and attenuation with a reduced reference x-ray tube 
electric current of 50 mA was performed before PET examination. PETexamination was done 
directly thereafter, followed by a diagnostic quality CT. The PET acquisition conditions were 
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the following: 3D, 3 min per bed position, during quiet normal breathing. The PET images 
were reconstructed using manufacturer's 2D-OSEM algorithm (4/8 iteration/subset) using a 5 
mm postreconstruction smoothing Gaussian filter; image matrix size, 168x168; slice 
thickness, 5 mm. The correction for scattered radiation, acquisition dead time and random 
coincidences was done. 
3.3 PET IMAGE ANALYSIS 
In each PET examination, volumes of interest (VOIs) were drawn to include the tumours, 
using the commercial software, and the SUV of the pixel with the highest radioactivity 
concentration (SUVmax) was registered.  The volume of the lesion (metabolic tumor volume 
for 
18
F-FDG and somatostatin receptor volume for 
68
Ga-DOTATOC) was recorded and 
approximated by using the ellipsoid formula and measurements of three orthogonal axes in 
the CT examinations. In study II, the SUR, defined as the tumor SUVmax divided by the mean 
SUV in normal liver tissue, was calculated for all patients and tracers. 
3.4 PARTIAL VOLUME CORRECTION FOR TRACER UPTAKE 
MEASUREMENTS 
The SUVmax values were corrected for PVE by applying lesion volume specific recovery 
coefficients, based on previous measurements, utilising a NEMA IEC body phantom filled 
with 
18
F and 
68
Ga, respectively
50
. 
The six spheres of the phantom (with 1.0, 1.3, 1.7, 2.2, 2.8 and 3.7 cm inner diameter) were 
homogeneously filled with radiotracer (
18
F-FDG and 
68
Ga-DOTATOC, respectively), at 
equal concentration, so that all PET image pixel values obtained within each sphere would 
have the same SUV = 1. No background activity was used. The protocol for acquisition 
described above was used for the phantom experiments. The PET images were reconstructed 
using manufacturer's 2D-OSEM algorithm (4/8 iteration/subset) using a 5 mm 
postreconstruction smoothing Gaussian filter; image matrix size, 168x168; slice thickness, 5 
mm. VOIs corresponding with the sphere contours were automatically created for each 
sphere of the phantom by using the phantom CT image, and the average SUV for each VOI 
was recorded. PET image recovery coefficients as a function of object size were then 
obtained as the ratio of the expected SUV = 1 for each sphere size and the measured mean 
SUV for each sphere size. 
3.5 IMMUNOHISTOCHEMISTRY AND HISTOPATHOLOGY 
Study I:  The PCs were classified as TC or AC based on the World Health Organisation’s 
criteria
57
. As an additional measure of proliferation, the proliferation marker Ki-67 was 
expressed in PCs as the percentage of positively stained cells among the total number of cells 
within at least 10 randomly selected high power fields.   
Study II:  Consecutive sections from formalin-fixed and paraffin-embedded tumour tissue 
were subjected for immunohistochemical visualisation of the SSTR subtypes, comprising 
SSTR 1-5, following the standard IHC protocols at the Karolinska University Hospital.  
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IHC reactions were independently scored by two pathologists (KD and MB), both blinded for 
the results of PET analysis. IHC reactions were independently analysed by counting multiple 
regions of highest labelling density. SSTR subtypes 1 and 3 were not significantly expressed 
in any individual of this cohort.  
The scoring parameters included the percentage of positive cells where 0 corresponds to no 
positive cells; 1≤10% positive cells; 2=11-50% positive cells; 3=51-80% positive cells; 
4>80% positive cells. The intensity of staining was graded 0= no staining; 1= mild staining 
intensity; 2= moderate staining intensity; 3= intense staining reaction. Immunoreactive score 
(IRS) was calculated by multiplying the percentage of positive cells with the staining 
intensity. The resulting IRS ranged 0 to 12, and was stratified as [0-1]= negative 
immunoreactivity, [2-3]= mild immunoreactivity, [4-8]= moderate immunoreactivity and [9-
12]= strong immunoreactivity. As the final step of the evaluation, the specific SSTR subtype 
immunohistophatological expression was then considered positive if IRS≥4 or negative if 
IRS<4.  
Tumour classification in TC or AC was performed from the individual pathological-
anatomical diagnosis (based on the World Health Organisation’s criteria8). The Ki-67 
labelling   index was determined and expressed as the percentage of positively stained cells 
out of the total number of cells within at least 10 high power fields. 
The PC were then subclassified into three groups according to their Ki-67 labelling   index ; 
the Low grade group (corresponding to tumour cells with Ki-67 <2%); the Intermediate grade 
(corresponding to tumour cells with Ki-67 [2-20%]) and the High grade (Ki-67 >20%) (Table 
1). To note as a terminology issue – the terms Low grade, Intermediate grade, High grade, 
devised and used in the text (Table 1), are not the same as tumour characteristics by 
aggressiveness, where TCs are considered to be low-grade, ACs - intermediate-grade, and 
LCNECs/SCLCs high-grade malignant
9
. 
  
 12 
Table 1. Patient characteristics, histopathology and devised tumour grading   
Patient  Histopatho-  Ki-67  Tumour group   
(age, years;  logical  (%)  based on KI-67 labelling index 
sex)  examination        
1. (77; F)  TC   1  Low grade    
2. (18; M)  TC   3  Intermediate grade  
3. (39; F)  TC*   <5  Intermediate grade  
4. (55; M)  TC   3    Intermediate grade  
5. (55;M)  TC   3  Intermediate grade  
6. (73; F)  AC*   10  Intermediate grade  
7. (52; M)  AC   1   Low grade   
8. (71; M)  TC*   <2   Low grade   
9. (33; F)  TC   3   Intermediate grade  
10. (74; M)  TC   1  Low grade   
11. (81; F)  TC   <2   Low grade   
12. (71; F)  TC   8  Intermediate grade  
13. (62; M)  TC   1   Low grade   
14. (43; M)  TC   <1  Low grade   
15. (44; M)  TC   2  Intermediate grade  
16. (40; F)  TC   10  Intermediate grade  
17. (48; M)  TC   4  Intermediate grade  
18. (73; M)  TC   5  Intermediate grade  
19. (76; M)  TC   1  Low grade  
20. (69; M)  AC   7  Intermediate grade  
21. (68; M)  TC   <1  Low grade   
22. (71; F)  AC*   45  High grade   
23. (72; F)  TC   1  Low grade   
24. (63; F)  TC   <1  Low grade   
25. (44; M)  AC   <2  Low grade   
26. (19; M)  TC   4  Intermediate grade  
 *, with metastasis; AC, atypical carcinoid; TC, typical carcinoid; Low grade, Ki-67 labelling   
index <2%; Intermediate grade, Ki-67 labelling   index [2-20%]; High grade, Ki-67 labelling   
index >20%  
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3.6 STATISTICAL ANALYSIS 
Study I:  The PVE corrected PET results were grouped, as PCs and hamartomas, and the 
SUVmax. Statistical differences between groups were tested with p<0.05 as significant level 
for all tests. The statistical differences in SUVmax between hamartomas and PCs and between 
hamartomas and periferal PCs were investigated using a t-test. To evaluate statistical 
differences in SUVmax between central and peripheral PCs as well as between TCs and ACs a 
non-parametric Wilcoxon rank sum test was used. For pooled PCs the linear correlation 
between the SUVmax and Ki-67 labelling index  was tested. 
Study II:  The tracer uptake was characterised by the standard uptake ratio (SUR), defined in 
the study as the ratio of activity concentrations in tumour and normal liver tissue (the tumor 
SUVmax divided by the mean SUV in normal liver tissue). The relationships between PET 
measurements and PC SSTR profile, grading (based on KI-67 labelling  index) and type were 
analysed using one-way analysis of variance (ANOVA) with p<0.05 as significant level. 
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4 RESULTS 
4.1 STUDY I 
51 patients with pulmonary hamartomas and 36 patients with PCs were evaluated in this 
study. The tumour sizes varied between 7 and 53 mm. The mean (range) size for hamartomas 
was 16 (7-34) mm, for PCs 25 (8-53) mm. 
Among the PCs (mean SUVmax 3.9), 25 were classified as TC (mean SUVmax 3.9), six as TC 
with lymph node metastasis (mean SUVmax 3.9), two as AC and three as AC with lymph node 
metastasis. In total, 31 patient in category pooled TCs (mean SUVmax 3.8), and five patients 
in pooled ACs (mean SUVmax 5.0). Of 36 pooled (periferal and central) PCs, 23 were 
centrally located (mean SUVmax 4.0) and 13 (eleven TCs, one AC and one AC with 
metastasis) peripherally located (mean SUVmax 3.9). Compared to the pulmonary hamartomas 
(mean SUVmax 1.4), the PVE corrected SUVmax was significantly higher in the pooled PCs (p 
≤ 0.00001), and in the peripheral PCs (p ≤ 0.00001). No statistically significant difference 
was found in SUVmax at group level between centrally and peripherally located PCs (a non 
parametric Wilcoxon rank sum test, p = 0.8). 
The SUVmax in the ACs and TCs was similar because of the large variation in the data (mean 
± standard deviation, 5.0 ± 2.6 and 3.8 ± 1.9, respectively) (p = 0.11), with similar results 
when testing for differences between ACs and TCs with metastasis. 
The Ki-67 was lower in TCs (with and without metastasis) (mean 2%, range 0 -12%), than 
for the ACs (with and without metastasis) (mean 10%, range 3-20%), (p = 0.0054). No 
correlation was found between SUVmax for pooled PCs and Ki-67 labelling index  (linear 
coefficient of determination R2 = 0.003). 
A SUVmax of 1.5, similar to the average SUVmax for the hamartomas, was applied as a cutoff 
for malignancy.  
The resulting sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) for 
18
F-FDG PET/CT to differ PCs from hamartomas were 92%, 69%, 67% and 
92%, respectively. 
4.2 STUDY II 
Histopathological examination resulted in 21 patients with TC and five patients with AC 
(Table 1). Four patients had metastases. Two patients showed spread disease with distant 
metastases: one with liver metastases and the other with brain metastases; whereas two 
patients had regional lymph node metastases. 
Assessment of lung lesions in our study comprised an evaluation of Ki-67  labelling   index  
and immunohistopathological expression of SSTRs in PCs and PET/CT for findings of 
focally increased radiotracer (
68
Ga-DOTATOC and 
18
F-FDG) uptake those are correlated to 
the IHC and histopathological examination.  
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Figure 2 shows the distribution of PET derived SUR for 
68
Ga-DOTATOC and 
18
F-FDG as a 
function of histopathological tumour classification (TC/AC). PET/CT could not distinguish 
ACs from TCs. The tracer accumulation in TCs and ACs were similar for 
68
Ga-DOTATOC, 
median SUR 4.6 and 4.8, respectively (p>0.05). Likewise, the tracer accumulation in TCs and 
ACs were similar for 
18
F-FDG, median SUR 1.4 and 2.4, respectively (p>0.05).  However, in 
the TCs the 
68
Ga-DOTATOC SUR was significantly higher than the 
18
F-FDG SUR 
(p=0.0006), but not in AC (p>0.05).  
The outcome for the IHC results and the three respective receptor subtypes, SSTR2, SSTR4 
and SSTR5 were grouped in combinations positive (+) or negative (-) for subtypes [SSTR2, 
SSTR4, SSTR5] with the following results: [---], n=3; [+--], n=14; [++-], n=2; [+-+], n=6 and 
[-+-], n=1.  
SSRT subtypes 1 and 3 were not significantly expressed in any of the patients of this cohort. 
 
Figure 2. Distribution of PET image derived standard uptake ratios (SUR) of 
68
Ga-
DOTATOC and 
18
F-FDG in PCs, grouped according to histopathological examination as 
typical (TC) and atypical (AC) carcinoids. The median of the distribution is represented by 
the line inside the box. An outlier is indicated with a cross. The error bars represent standard 
deviation of the group. 
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Table 2 shows the PET image derived mean SUR values for 
68
Ga-DOTATOC and 
18
F-FDG 
for the different combinations of SSTR subtype expression.    
Table 2. The distribution of the mean SUR in tumours across different combinations of 
SSTR expression and tumour grading (Low grade, Ki-67 <2%; Intermediate grade, Ki-67 [2-
20%]; High grade, Ki-67 >20% ) in tumours for 
68
Ga-DOTATOC and 
18
F-FDG. 
SSTR [SSTR2,SSTR4,SSTR5]  SUR for 
68
Ga-DOTATOC SUR for 
18
F-FDG 
[+-+] Low+Intermediate+High grade 11.5     1.4 
[+-+] Low grade      15.8     1.4 
[+-+] Intermediate grade    3.1     1.5 
[+-+] High grade     NA     NA 
[+--]  Low+Intermediate+High grade 9.9     1.6 
[+--]  Low grade      8.6     1.3 
[+--]  Intermediate grade   10.6     1.7 
[+--]  High grade     NA     NA 
[++-] Low+Intermediate+High grade 5.9     2.0 
[++-] Low grade      5.9     2.0 
[++-] Intermediate grade   NA     NA 
[++-] High grade     NA     NA 
[---]   Low+Intermediate+High grade 0.5     2.5 
[---]   Low grade                     0.6     1.3   
[---]   Intermediate grade   0.4     2.8 
[---]   High grade     0.5     3.4 \ 
[-+-]  Low+Intermediate+High grade 0.3     5.7 
[-+-]  Low grade      NA     NA 
[-+-]  Intermediate grade   0.3     5.7 
[-+-]  High grade     NA     NA 
NA, not applicable 
 
The 
68
Ga-DOTATOC SUR was significantly higher for tumours positive for SSTR subtypes 
2 and  SSTR subtypes (2 and 5) as compared to tumours not expressing these SSTR subtypes 
(p=0.037).  An inverse correlation was found for 
18
F-FDG, where the mean SUR value in 
tumours with positive expression of the SSTR subtypes 2 and  SSTR subtypes (2 and 5) was 
significantly lower than in those with negative expression (p=0.005). This relation between 
68
Ga-DOTATOC and 
18
F-FDG SUR and SSTR profile is also demonstrated in Figure 3. This 
figure shows a heatmap of the mean tumour SUR for 
68
Ga-DOTATOC and 
18
F-FDG for the 
different SSTR subtypes. Figure 3 clearly reveals that the tumour uptake patterns of 
68
Ga-
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DOTATOC and 
18
F-FDG show an inverse imaging phenotype in relation to the SSTR 
subtype expression. Positive SSTR subtype 2 (or 2 and 5) expression profile is related to high 
68
Ga-DOTATOC accumulation and low 
18
F-FDG uptake and conversely, negative SSTR 2 
(or 2 and 5) expression results in low 
68
Ga-DOTATOC accumulation and high 
18
F-FDG 
uptake (p<0.05). 
Ki-67  labelling index  was significantly higher for tumors not expressing SSTR 2 and 5 as 
compared to the other subgroups, [+-+], [+--] and [++-] (p=0.03). 
According to the tumour subclassification, as formulated in the study with respect to Ki-67 
labelling   index, 12 patients were classified as Low grade group, 13 patients as Intermediate 
grade group and only one patient as High grade group (Table 1). Figure 4 shows the 
distribution of 
68
Ga-DOTATOC SUR and 
18
F-FDG SUR as a function of the 
subclassification with respect to Ki-67 labelling   index  grading, and illustrates the inverse 
imaging phenotype of 
68
Ga-DOTATOC and 
18
F-FDG regarding their respective 
accumulation in High and Low grade tumours (p<0.01).   
Table 2 reveals differences in the relation between the accumulation of 
68
Ga-DOTATOC and 
18
F-FDG in PCs, grouped according to their grading (subclassification) and SSTR expression 
profile. The groups of Low/Intermediate grade PCs with strong SSTR 2 (or 2 and 5) 
expression presented phenotypes characterised by a strong 
68
Ga-DOTATOC accumulation 
and very low 
18
F-FDG metabolic avidity (p=0.006/0.002). The groups of PCs subclassified as 
Intermediate/High grade with no SSTR 2 and 5 expression showed a strong  
18
F-FDG 
metabolic avidity and very low 
68
Ga-DOTATOC  accumulation (p=0.016). The group of Low 
grade PCs with no SSTR 2 and 5 expression showed both low accumulation of 
68
Ga-
DOTATOC and low 
18
F-FDG avidity. 
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Figure 3.  Heatmap of the mean tumour SUR for 
68
Ga-DOTATOC and 
18
F-FDG in patients 
with similar somatostatin receptor (SSTR) subtype expression profile, positive (+) or negative 
(-) for subtypes [SSTR2, SSTR4, SSTR5]. 
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Figure 4. Distribution of PET image derived SUR of 
68
Ga-DOTATOC and 
18
F-FDG 
stratified according to the tumour classification with respect to Ki-67 labelling index. The 
median of the distribution is represented by the line inside the box. An outlier is indicated 
with a cross. The error bars represent standard deviation of the group. 
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5 DISCUSSION 
Study I: Since the diagnosis was not achieved preoperatively, it became apparent afterwards 
that the surgical resection had been unnecessary in all 51 patients with benign lung pathology. 
Due to the increasing use of high spatial resolution multidetector CT, a substantial number of 
lung lesions are detected which are in need of characterisation
58
. For each lesion, its nature 
and malignancy potential must be assessed radiologically by evaluating the lesion size, 
tumour outline (smooth, rough, spiculated), the presence of calcifications and fat, signs of 
infiltration into adjacent structures, enlarged regional lymph nodes and distant metastases. 
Management strategies for solitary lung lesions include follow-up CT, 
18
F-FDG PET/CT and 
/or biopsy.  
While centrally located carcinoids are frequently symptomatic and easily assessable for 
diagnostic biopsy, up to 20% of carcinoids show peripheral location and appear radiologically 
as a solitary pulmonary nodule. These lesions are a diagnostic challenge, presenting 
difficulties for cytological and histopathological verification by CT-guided percutaneous 
needle biopsy
59
.  Peripherally located carcinoids (13 patients) in our study were distinguished 
from lesions of benign origin as based on their mean SUVmax on 
18
F-FDG PET
55
. PCs have 
traditionally been described as tumours with slow growth and low metabolic activity with 
low or even absent 
18
F-FDG uptake
13
. Early 
18
F-FDG PET studies showed low sensitivity for 
detection of PCs and the method has therefore been considered to have a limited role in the 
diagnostic work-up of these tumours. However, PCs can be 
18
F-FDG avid to indicate 
malignancy
14-18,20
. The present results show that there was significantly higher 
18
F-FDG 
uptake in PCs than in hamartomas and with a negative predictive value (NPV) of 92%, the 
risk of missing a PC is low
55
.  A retrospective evaluation of the visual grading of the 
18
F-FDG 
uptake in 16 subsequently resected PCs, found an overall 75% sensitivity of 
18
F-FDG PET to 
detect PCs, with a trend towards higher sensitivity for the 5 ACs (80%) as compared to the 11 
TCs (73%)
16
. Data from a study including 29 PCs (23 TCs and 6 ACs), showed that the mean 
SUVmax on 
18
F-FDG PET in ACs was significantly higher than in TCs, 8.1 and 2.7 
respectively
60
. Indeed, the SUVmax of 
18
F-FDG did not differentiate the 26 TCs from the 5 
ACs in our study
55
. 
The size of the lesions in our study varied between 7 and 53 mm, where the size of the the 
smallest is similar to the intrinsic PET system spatial resolution used (6 mm full width at half 
maximum in the center of the field of view). It is known that quantitative measurement of 
SUV in tumours is highly dependent on lesion size
61
, and the PVE has a major effect on this 
measurement. Lesions below or close to the intrinsic spatial resolution of PET cameras might 
be detected, but show an apparent 
18
F-FDG uptake much lower than the actual radioactivity 
concentration.  
18
F-FDG uptake in the tumour higher than that of the normal mediastinal blood pool is often 
used as an indication of pulmonary tumours
61
. To establish cutoff for positive 
18
F-FDG 
uptake in our study, two factors were considered more relevant: the NPV of 
18
F-FDG PET 
and the mean SUVmax for hamartomas. The cutoff of 1.5 for positive radiotracer uptake 
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influenced the NPV (92%) in our analysis. There are strengths with our study but there are 
also limitations. The advantages are that the present study allows for better statistical power 
as the study comprises a large number of patients. We have also corrected the SUV 
measurements for the PVE to enable a more precise quantification of 
18
F-FDG uptake and 
make the comparisons between tumour subgroups more accurate. However, ACs could not be 
differentiated from TCs.The limitations are the retrospective nature of our analysis and, 
consequently, that the acquired PET data are based on an examination protocol without 
breathing gating in order to make the SUV measurements even more precise. The relatively 
low PPV (67%) indicated a fairly high rate of false-positive results, but one can be confident 
that 
18
F-FDG negative PET corresponds with a cancer-free status. 
Study II:  In this prospective study, the accumulation of 
68
Ga-DOTATOC and 
18
F-FDG in 
PCs was compared and correlated with their immunohistochemical SSTR profile, grade 
according to Ki-67 and tumour type (TC/AC). This study included 26 verified PCs. The low 
incidence of PCs makes it difficult to perform prospective studies in large patient groups. 
Previously published reports on 
68
Ga-DOTATOC PET/CT of respiratory tract neoplasms 
included a limited number of patients with PCs
12,18,39,40
. The results of the present study in 26 
patients should therefore be regarded in this perspective. 
Consistent with previous reports
62
, the Ki-67 in our cohort showed large variations, ranging 1 
to 45% (Table 1). Currently, Ki-67 labelling index is not clinically recommended to reliably 
differentiate between low-grade lung neuroendocrine tumours (TCs) and intermediate-grade 
lung neuroendocrine tumours (ACs). There are also several problems regarding the utility of 
Ki-67 labelling index due to both biological and methodological reasons. The sampling error 
in connection with biopsy may, because of tumour heterogeneity, lead to varying results and 
the Ki-67 labelling index and the tumour can also change over time. Earlier reports on the 
relationship between the tumour 
68
Ga-DOTA-SSAs accumulation and tumour grade have 
also shown large discrepancies
23,27,42,45
. This may be due to the use of different 
immunohistochemical techniques and counting methods, together with a lack of consensus 
regarding the Ki-67 index cutoff values and varying characterisation of lung neuroendocrine 
neoplasms
63,64,65
. The role of Ki-67 labelling index  in tumour grading, as well as an 
independent prognostic parameter in predicting survival, is to date not well established
62,66,67
. 
Additional prospective studies are therefore warranted to generate more data on Ki-67  in 
lung neuroendocrine tumours for purposes of staging and prognosis
68
. DOTATOC, as 
reported in literature, shows a high affinity for SSTR2 and SSTR5
24,28,29
. This was confirmed 
in the present study. For measurements of tracer accumulation in the tumours we applied 
SUR, which was based on the tumour-to-normal liver ratio. The normal liver tissue was 
chosen as the reference because of its low tracer uptake variation between patients. 
In our cohort, the 
68
Ga-DOTATOC accumulation was positively correlated with the 
immunohistochemical expression of SSTR2 and co-expression of SSTR subtypes 2 and 5, in 
line with previously published results
24,26-29,42
. In our study, the 
68
Ga-DOTATOC 
accumulation was found to decrease with increasing PC grading and inversely the 
18
F-FDG 
avidity increased with increasing PC grading. These results are in accordance with previous 
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publications
20,69
. For neuroendocrine neoplasms in general, low-grade tumours show high 
68
Ga-DOTA-SSA accumulation and low 
18
F-FDG uptake, with the reverse situation in high-
grade neuroendocrine neoplasms. Table 2 in our study shows an inverse uptake pattern 
between 
68
Ga-DOTATOC and 
18
F-FDG in relation to the PCs SSTR expression profile and 
tumour grading genotypes. Even though low-grade PCs are being considered less well suited 
for tumour detection by 
18
F-FDG-PET/CT, most tumours in the present study showed some 
degree of 
18
F-FDG uptake. Then PET with somatostatin analog is of limited value in patients 
with high-grade neuroendocrine neoplasms, 
18
F-FDG PET may be more suitable. Thus, 
whole-body PET/CT combining 
68
Ga-DOTATOC and 
18
F-FDG opens the possibility to 
characterise different NET subtypes, and to identify tumour heterogeneity, by quantifying 
SSTR expression and tumour metabolism, to individualise the treatment and, although not 
applicable in the present cohort, also achieve prognostic information. Different PC 
accumulation could theoretically be encountered with the use of different 
68
Ga-DOTA-SSA 
preparations with varying affinities for the different SSTR subtypes.  
As initially discussed, this PET/CT study was performed in a small patient cohort and this 
limits the statistical power for some of the analyses. Also, the full spectrum of 
immunohistochemical SSTR profiles was not represented (SSTR subtypes 1 and 3 were not 
significantly expressed in any individual of this cohort) and the acquired PET data are based 
on an examination protocols without breathing gating.  
Current WHO classification of tumours of the lung, pleura, thymus and heart requires 
grouping together PCs (AC and TC), SCLC and LCNEC in one neuroendocrine tumors 
category
8
. On molecular basis, however, LCNEC, SCLC and PCs are separate biological 
entities
9
. The alternative view suggests that TC and AC have a latent propensity for 
progression towards high-grade neuroendocrine neoplasms, by evolution of AC to SCLC and 
TC to LCNEC, according to the concept of secondary high-grade neuroendocrine neoplasms 
developing from preexisting PCs
63,70
. Molecular mechanisms of SSTR physiology and 
pathogenesis of neuroendocrine neoplasm are under investigation as a part in the 
development strategies in diagnosis and treatment of neuroendocrine tumours
71,72
. The recent 
recommendations by the European Neuroendocrine Tumor Society, advocate a 
multidisciplinary approach and long-term follow-up for TC and AC
73
. In this framework, 
dual tracer PET/CT in clinically suspected PCs, reflecting tumour SSTR density with 
68
Ga-
DOTATOC, and tumour metabolism with 
18
F-FDG, can be helpful for imaging diagnosis and 
staging and to acquire prognostic information for treatment individualisation and follow up. 
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6 CONCLUSIONS 
Study I:  It was possible to discriminate PCs from pulmonary hamartomas using 
18
F-FDG 
PET measurements of 
18
F-FDG uptake by applying a PVE-corrected SUVmax of 1.5 as cutoff 
in the tumours. 
 18
F-FDG PET/CT can not distinguish ACs from TCs. 
 
Study II: 
18
F-FDG and 
68
Ga-DOTATOC PET measurements do not allow for separating 
ACs from TCs. 
18
F-FDG and 
68
Ga-DOTATOC accumulation (devised as standardise uptake 
ratio) was similar in TCs and ACs, although in TCs the 
68
Ga-DOTATOC SUR was 
significantly higher than the 
18
F-FDG SUR, but not in ACs.  
The PC genotypes were reflected in the imaging phenotypes with inverse 
68
Ga-DOTATOC 
and 
18
F-FDG accumulation patterns. The degree of 
68
Ga-DOTATOC and 
18
F-FDG uptake 
was found to reflect the PC´s individual combinations of immunohistochemical SSTR profile 
and tumour grading based on Ki-67 labelling index. 
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